Abstract
Background Several Intensive Care Units (ICU) have been overwhelmed by the surge of COVID-19 patients thus necessitating to extend ventilation capacity outside the ICU where air and oxygen pressure are not always available. Transport ventilators requiring only O2 source may be used to deliver volume-controlled ventilation.
Objective To evaluate the performances of four transport ventilators compared to an ICU ventilator simulating severe respiratory conditions.
Materials and methods Two pneumatic transport ventilators, (Oxylog 3000, Draeger; Osiris 3, Air Liquide Medical Systems) and two turbine transport ventilators (Elisee 350, ResMed; Monnal T60, Air Liquide Medical Systems) were compared to an ICU ventilator (Engström Carestation – GE Healthcare) using a Michigan training test lung. We tested each ventilator with different set volumes Vtset (350, 450, 550 ml) and different compliances (20 or 50 ml/cmH2O) and a resistance of 15 cmH2 0/L/sec based on values recently described in COVID-19 Acute Respiratory Distress Syndrome. Volume error was measured, as well as the trigger time delay during assist-control ventilation simulating spontaneous breathing activity with a P0.1 of 4 cmH20.
Results Grouping all conditions, the volume error was 2.9 ± 2.2 % for Engström Carestation; 3.6 ± 3.9 % for Osiris 3; 2.5 ± 2.1 % for Oxylog 3000; 5.4 ± 2.7 % for Monnal T60 and 8.8 ± 4.8 % for Elisee 350. Grouping all conditions, trigger delay was 42 ± 4 ms, 65 ± 5 ms, 151 ± 14 ms, 51 ± 6 and 64 ± 5 ms for Engström Carestation, Osiris 3, Oxylog 3000, Monnal T60 and Elisee 350, respectively.
Conclusions In special surge situations such as COVID-19 pandemic, most transport ventilators may be used to safely deliver volume-controlled ventilation in locations where only oxygen pressure supply is available with acceptable volume accuracy. Performances regarding triggering function are generally acceptable but vary across ventilators.
Competing Interest Statement
DS reports grants from Fisher and Paykel and travel fees from Air Liquide Medical Systems. JCR reports part time salary for research activities (Med2Lab) from Air Liquide Medical Systems and Vygon. AL is PhD student in the Med2Lab and in Vent Lab in the Angers ICU and is partially funded by Air Liquide Medical Systems. AB is master student from the Telecom-Physic-Strasbourg Strasbourg University France. FB reports personal fees from Löwenstein Medical, travel fees from Draeger and research support from Covidien, GE Healthcare and Getinge Group, outside this work. AM reports personal fees from Draeger, Faron Pharmaceuticals, Air Liquide Medical Systems, Pfizer, Resmed and Draeger and grants and personal fees from Fisher and Paykel and Covidien, outside this work. LB has received research grants and/or equipment for his research laboratory from Medtronic Covidien (PAV), Air Liquide (helium, CPR), Fisher Paykel (high flow), General Electric (lung volume; ultrasound), Sentec (PtcCO2) and Philips (sleep). All other authors declare no competing interests.
Funding Statement
This study did not receive any grant or financial support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Non Applicable -> bench study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred in the manuscript can be provided by the authors on demand.